BCRX
Price
$6.29
Change
-$0.19 (-2.94%)
Updated
May 17, 6:59 PM EST
74 days until earnings call
KALV
Price
$11.92
Change
-$0.15 (-1.24%)
Updated
May 17, 6:59 PM EST
47 days until earnings call
Ad is loading...

BCRX vs KALV

Header iconBCRX vs KALV Comparison
Open Charts BCRX vs KALVBanner chart's image
BioCryst Pharmaceuticals
Price$6.29
Change-$0.19 (-2.94%)
Volume$2.76M
CapitalizationN/A
KalVista Pharmaceuticals
Price$11.92
Change-$0.15 (-1.24%)
Volume$241.5K
CapitalizationN/A
View a ticker or compare two or three
BCRX vs KALV Comparison Chart

Loading...

BCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
KALVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
BCRX vs. KALV commentary
May 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCRX is a Hold and KALV is a Hold.

COMPARISON
Comparison
May 19, 2024
Stock price -- (BCRX: $6.28 vs. KALV: $11.92)
Brand notoriety: BCRX: Notable vs. KALV: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCRX: 117% vs. KALV: 81%
Market capitalization -- BCRX: $1.3B vs. KALV: $502.88M
BCRX [@Biotechnology] is valued at $1.3B. KALV’s [@Biotechnology] market capitalization is $502.88M. The market cap for tickers in the [@Biotechnology] industry ranges from $586.12B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCRX’s FA Score shows that 1 FA rating(s) are green whileKALV’s FA Score has 0 green FA rating(s).

  • BCRX’s FA Score: 1 green, 4 red.
  • KALV’s FA Score: 0 green, 5 red.
According to our system of comparison, BCRX is a better buy in the long-term than KALV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCRX’s TA Score shows that 5 TA indicator(s) are bullish while KALV’s TA Score has 7 bullish TA indicator(s).

  • BCRX’s TA Score: 5 bullish, 5 bearish.
  • KALV’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, KALV is a better buy in the short-term than BCRX.

Price Growth

BCRX (@Biotechnology) experienced а +18.05% price change this week, while KALV (@Biotechnology) price change was -1.32% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.41%. For the same industry, the average monthly price growth was +2.86%, and the average quarterly price growth was +60.72%.

Reported Earning Dates

BCRX is expected to report earnings on Aug 01, 2024.

KALV is expected to report earnings on Sep 05, 2024.

Industries' Descriptions

@Biotechnology (+1.41% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for BCRX with price predictions.
OPEN
A.I.dvisor published
a Summary for KALV with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BCRX($1.3B) has a higher market cap than KALV($503M). BCRX YTD gains are higher at: 4.841 vs. KALV (-2.694).
BCRXKALVBCRX / KALV
Capitalization1.3B503M258%
EBITDAN/AN/A-
Gain YTD4.841-2.694-180%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
BCRX vs KALV: Fundamental Ratings
BCRX
KALV
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
2
Undervalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10098
PRICE GROWTH RATING
1..100
4251
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCRX's Valuation (2) in the Biotechnology industry is somewhat better than the same rating for KALV (60) in the Pharmaceuticals Other industry. This means that BCRX’s stock grew somewhat faster than KALV’s over the last 12 months.

BCRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that BCRX’s stock grew similarly to KALV’s over the last 12 months.

KALV's SMR Rating (98) in the Pharmaceuticals Other industry is in the same range as BCRX (100) in the Biotechnology industry. This means that KALV’s stock grew similarly to BCRX’s over the last 12 months.

BCRX's Price Growth Rating (42) in the Biotechnology industry is in the same range as KALV (51) in the Pharmaceuticals Other industry. This means that BCRX’s stock grew similarly to KALV’s over the last 12 months.

BCRX's P/E Growth Rating (100) in the Biotechnology industry is in the same range as KALV (100) in the Pharmaceuticals Other industry. This means that BCRX’s stock grew similarly to KALV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCRXKALV
RSI
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
88%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
88%
Bearish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
81%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 12 days ago
78%
Declines
ODDS (%)
Bearish Trend 11 days ago
81%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
Aroon
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
85%
View a ticker or compare two or three
Ad is loading...
BCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
KALVDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFGAX12.060.05
+0.42%
JHancock Fundamental Global Fran A
TCVYX23.440.05
+0.21%
Touchstone Mid Cap Value Y
MGRTX42.710.06
+0.14%
MFS International Growth R3
ARRKX13.990.01
+0.07%
AB Global Real Estate Investment K
GSBUX25.640.01
+0.04%
Goldman Sachs Income Builder R6

BCRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCRX has been loosely correlated with NTLA. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if BCRX jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCRX
1D Price
Change %
BCRX100%
-2.94%
NTLA - BCRX
49%
Loosely correlated
+0.19%
VCYT - BCRX
46%
Loosely correlated
-2.22%
XNCR - BCRX
44%
Loosely correlated
+2.54%
BEAM - BCRX
42%
Loosely correlated
+3.49%
FOLD - BCRX
42%
Loosely correlated
+0.74%
More

KALV and

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-1.24%
ATXS - KALV
39%
Loosely correlated
+1.17%
VSTM - KALV
37%
Loosely correlated
-5.19%
PLRX - KALV
37%
Loosely correlated
-2.18%
SNDX - KALV
36%
Loosely correlated
-3.01%
RYTM - KALV
36%
Loosely correlated
-3.09%
More